ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The company was founded based on the research of Prof. Gideon Gross of the Migal Research Institute and has been incubated in the FutuRx incubator since 2017. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/20/20 | $18,000,000 | Series A |
Bukwang Pharmaceutical Hayan Health Networks Johnson & Johnson Development Corporation (JJDC) JVC Investment Partners Novartis OrbiMed Advisors RM Global Partners Takeda Ventures | undisclosed |
